CA3047171A1 - Method for preventing and treating pathological renal tissue injury - Google Patents

Method for preventing and treating pathological renal tissue injury Download PDF

Info

Publication number
CA3047171A1
CA3047171A1 CA3047171A CA3047171A CA3047171A1 CA 3047171 A1 CA3047171 A1 CA 3047171A1 CA 3047171 A CA3047171 A CA 3047171A CA 3047171 A CA3047171 A CA 3047171A CA 3047171 A1 CA3047171 A1 CA 3047171A1
Authority
CA
Canada
Prior art keywords
plasminogen
renal
drug
subject
renal tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3047171A
Other languages
English (en)
French (fr)
Inventor
Jinan Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen International Ltd
Original Assignee
Talengen International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen International Ltd filed Critical Talengen International Ltd
Publication of CA3047171A1 publication Critical patent/CA3047171A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3047171A 2016-12-15 2017-06-19 Method for preventing and treating pathological renal tissue injury Abandoned CA3047171A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016110169 2016-12-15
CNPCT/CN2016/110169 2016-12-15
CN2016110174 2016-12-15
CNPCT/CN2016/110174 2016-12-15
PCT/CN2017/089060 WO2018107700A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法

Publications (1)

Publication Number Publication Date
CA3047171A1 true CA3047171A1 (en) 2018-06-21

Family

ID=62557856

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3047171A Abandoned CA3047171A1 (en) 2016-12-15 2017-06-19 Method for preventing and treating pathological renal tissue injury
CA3047170A Abandoned CA3047170A1 (en) 2016-12-15 2017-06-19 Method for preventing and treating drug-induced renal injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3047170A Abandoned CA3047170A1 (en) 2016-12-15 2017-06-19 Method for preventing and treating drug-induced renal injury

Country Status (7)

Country Link
US (2) US20190343930A1 (https=)
EP (2) EP3556386A4 (https=)
JP (2) JP7182793B2 (https=)
CN (2) CN110167582A (https=)
CA (2) CA3047171A1 (https=)
TW (4) TW202123962A (https=)
WO (3) WO2018107699A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113456579B (zh) * 2021-07-12 2023-04-25 南开大学 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CN87104683A (zh) * 1986-05-15 1988-12-21 埃默里大学 改善血纤维蛋白溶解作用的组合物
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003210137A1 (en) * 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
EP1509236A4 (en) * 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
BR0316583A (pt) * 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
JP2008510814A (ja) * 2004-08-23 2008-04-10 ワイス Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
AU2007290881B2 (en) * 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
ES2516717T3 (es) * 2009-05-26 2014-10-31 Universidad De Salamanca Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
JP6085568B2 (ja) * 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
AU2012315586B2 (en) * 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
TN2016000048A1 (en) * 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
CA2939897A1 (en) * 2014-02-21 2015-08-27 Astellas Pharma Inc. New anti-human pai-1 antibody

Also Published As

Publication number Publication date
TWI661838B (zh) 2019-06-11
WO2018107695A1 (zh) 2018-06-21
JP7242057B2 (ja) 2023-03-20
CN110366427A (zh) 2019-10-22
CN110167582A (zh) 2019-08-23
JP2020502135A (ja) 2020-01-23
TW201822793A (zh) 2018-07-01
EP3556388A1 (en) 2019-10-23
WO2018107700A1 (zh) 2018-06-21
JP2020502134A (ja) 2020-01-23
TW201822794A (zh) 2018-07-01
JP7182793B2 (ja) 2022-12-05
CA3047170A1 (en) 2018-06-21
EP3556386A4 (en) 2020-07-08
US20190328848A1 (en) 2019-10-31
EP3556386A1 (en) 2019-10-23
TWI642441B (zh) 2018-12-01
WO2018107699A1 (zh) 2018-06-21
TW201822797A (zh) 2018-07-01
TW202123962A (zh) 2021-07-01
EP3556388A4 (en) 2020-07-08
US20190343930A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
US11090372B2 (en) Method of treating diabetic nephropathy comprising administering plasminogen
US11478535B2 (en) Method for preventing and treating fatty liver
HK1257234A1 (zh) 治疗冠状动脉粥样硬化及其并发症的药物及其用途
US20190343930A1 (en) Method for preventing and treating pathological renal tissue injury
HK1257591A1 (zh) 预防和治疗病理性肾组织损伤的药物及其用途
HK1257238A1 (zh) 预防和治疗脂质肾损伤的药物及其用途
HK1257235A1 (en) Medicine for treating atherosclerosis and complications of atherosclerosis and use of the medicine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190614

FZDE Discontinued

Effective date: 20231220